155 related articles for article (PubMed ID: 38319718)
1. Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer.
Wang J; Jiang Z; Wang K; Zheng Q; Jian J; Liu X; Chen Z; Yang R; Wang L
Aging (Albany NY); 2024 Feb; 16(3):2812-2827. PubMed ID: 38319718
[TBL] [Abstract][Full Text] [Related]
2. Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.
Sun YF; Chen L; Xia QJ; Wang TH
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10217-10234. PubMed ID: 37269345
[TBL] [Abstract][Full Text] [Related]
3. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
4. Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinoma.
Zhang R; Li Q; Yu X; Hou Y; Yan L; Gao Y; Ji L; Zhang X; Fang M; Huang L; Yu Z; Gao Y; Li M
Heliyon; 2023 Nov; 9(11):e22083. PubMed ID: 38034714
[TBL] [Abstract][Full Text] [Related]
5. A novel necroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma.
Wang J; Shen B; Liu X; Jiang J
Front Genet; 2022; 13():985191. PubMed ID: 36267408
[TBL] [Abstract][Full Text] [Related]
6. Construction of a necroptosis-related lncRNA signature to predict the prognosis and immune microenvironment of head and neck squamous cell carcinoma.
Huang J; Xu Z; Teh BM; Zhou C; Yuan Z; Shi Y; Shen Y
J Clin Lab Anal; 2022 Jun; 36(6):e24480. PubMed ID: 35522142
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction.
XiaYu K; GuoGang C; CanXuan L; WeiBin X
Dis Markers; 2022; 2022():2360299. PubMed ID: 35711565
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients.
Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B
Front Genet; 2022; 13():966896. PubMed ID: 36186456
[No Abstract] [Full Text] [Related]
9. Clinicopathological and Prognostic Value of Necroptosis-Associated lncRNA Model in Patients with Kidney Renal Clear Cell Carcinoma.
Gu J; He Z; Huang Y; Luan T; Chen Z; Wang J; Ding M
Dis Markers; 2022; 2022():5204831. PubMed ID: 35664432
[TBL] [Abstract][Full Text] [Related]
10. A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas.
Liu B; Liu Z; Feng C; Tu C
Front Genet; 2022; 13():899545. PubMed ID: 35795204
[No Abstract] [Full Text] [Related]
11. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel necroptosis-related lncRNA signature for prognosis prediction in esophageal cancer.
Liu Y; Hao H; Kang L; Zheng G; Guo X; Li B; Zhao H; Hao H
BMC Gastroenterol; 2022 Jul; 22(1):345. PubMed ID: 35840890
[TBL] [Abstract][Full Text] [Related]
13. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.
Yang B; Wang Y; Liu T; Zhang M; Luo T
Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403
[TBL] [Abstract][Full Text] [Related]
14. A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors.
Li H; Lv Z; Liu M
Medicine (Baltimore); 2023 Oct; 102(41):e35196. PubMed ID: 37832111
[TBL] [Abstract][Full Text] [Related]
15. A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer.
Jin Y; Li J; Tang C; He K; Shan D; Yan S; Deng G
Medicine (Baltimore); 2023 May; 102(18):e33664. PubMed ID: 37145007
[TBL] [Abstract][Full Text] [Related]
16. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
18. A New Prognostic Signature Constructed with Necroptosis-Related lncRNA in Bladder Cancer.
Yu Z; Lu B; Gao H; Liang R
J Oncol; 2022; 2022():5643496. PubMed ID: 36425941
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Prognosis and Immunotherapy of Osteosarcoma Based on Necroptosis-Related lncRNAs.
Wang G; Zhang X; Feng W; Wang J
Front Genet; 2022; 13():917935. PubMed ID: 35692813
[No Abstract] [Full Text] [Related]
20. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
